Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer

Christina Sayama, Matthew Willsey, Murali Chintagumpala, Alison Brayton, Valentina Briceño, Sheila L. Ryan, Thomas G. Luerssen, Steven W. Hwang, Andrew Jea

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Object: The aim of this study was to determine the safety of recombinant human bone morphogenetic protein-2 (rhBMP-2) use in posterior instrumented fusions in the pediatric population, focusing on cancer risk. In a previous study, the authors reported the short-term (mean follow-up of 11 months) safety and efficacy of rhBMP-2 in the pediatric age group. The present study reports their results with a minimum of 24 months' follow-up. methods: The authors retrospectively reviewed 57 consecutive cases involving pediatric patients who underwent posterior occiptocervical, cervical, thoracic, lumbar, or lumbosacral spine fusion from October 1, 2007, to June 30, 2011, at Texas Children's Hospital. Seven cases were excluded from further analysis because of loss to follow-up. Three patients died during the follow-up period and were placed in a separate cohort. results The patients' average age at the time of surgery was 11 years, 4 months (range 9 months to 20 years). The mean duration of follow-up was 48.4 months (range 24-70 months). Cancer status was determined at the most recent encounter with the patient and/or caretaker(s) in person, or in telephone follow-up. Twenty-four or more months after administration of rhBMP-2, there were no cases of new malignancy, degeneration, or metastasis of existing tumors. The cause of death of the patients who died during the study period was not related to BMP or to the development, degeneration, or metastasis of cancer. conclusions Despite the large number of adult studies reporting increased cancer risk associated with BMP use, the authors' outcomes with rhBMP-2 in the pediatric population suggest that it is a safe adjunct to posterior spine fusions of the occipitocervical, cervical, thoracic, lumbar, and lumbosacral spine. There were no new cases of cancer, or degeneration or metastasis of existing malignancies in this series.

Original languageEnglish (US)
Pages (from-to)4-13
Number of pages10
JournalJournal of Neurosurgery: Pediatrics
Volume16
Issue number1
DOIs
StatePublished - Jul 1 2015
Externally publishedYes

Fingerprint

Spine
Pediatrics
Incidence
Neoplasms
Neoplasm Metastasis
Thorax
Safety
recombinant human bone morphogenetic protein-2
Telephone
Population
Cause of Death
Age Groups

Keywords

  • Bone morphogenetic protein
  • Cancer
  • Complications
  • Malignancy
  • Neurosurgery
  • Oncology
  • Pediatric spine
  • RhBMP-2
  • Spinal fusion
  • Spinal instrumentation
  • Technique

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)

Cite this

Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer. / Sayama, Christina; Willsey, Matthew; Chintagumpala, Murali; Brayton, Alison; Briceño, Valentina; Ryan, Sheila L.; Luerssen, Thomas G.; Hwang, Steven W.; Jea, Andrew.

In: Journal of Neurosurgery: Pediatrics, Vol. 16, No. 1, 01.07.2015, p. 4-13.

Research output: Contribution to journalArticle

Sayama, Christina ; Willsey, Matthew ; Chintagumpala, Murali ; Brayton, Alison ; Briceño, Valentina ; Ryan, Sheila L. ; Luerssen, Thomas G. ; Hwang, Steven W. ; Jea, Andrew. / Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer. In: Journal of Neurosurgery: Pediatrics. 2015 ; Vol. 16, No. 1. pp. 4-13.
@article{030c3ea0b2a946989a973461f0333a7c,
title = "Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer",
abstract = "Object: The aim of this study was to determine the safety of recombinant human bone morphogenetic protein-2 (rhBMP-2) use in posterior instrumented fusions in the pediatric population, focusing on cancer risk. In a previous study, the authors reported the short-term (mean follow-up of 11 months) safety and efficacy of rhBMP-2 in the pediatric age group. The present study reports their results with a minimum of 24 months' follow-up. methods: The authors retrospectively reviewed 57 consecutive cases involving pediatric patients who underwent posterior occiptocervical, cervical, thoracic, lumbar, or lumbosacral spine fusion from October 1, 2007, to June 30, 2011, at Texas Children's Hospital. Seven cases were excluded from further analysis because of loss to follow-up. Three patients died during the follow-up period and were placed in a separate cohort. results The patients' average age at the time of surgery was 11 years, 4 months (range 9 months to 20 years). The mean duration of follow-up was 48.4 months (range 24-70 months). Cancer status was determined at the most recent encounter with the patient and/or caretaker(s) in person, or in telephone follow-up. Twenty-four or more months after administration of rhBMP-2, there were no cases of new malignancy, degeneration, or metastasis of existing tumors. The cause of death of the patients who died during the study period was not related to BMP or to the development, degeneration, or metastasis of cancer. conclusions Despite the large number of adult studies reporting increased cancer risk associated with BMP use, the authors' outcomes with rhBMP-2 in the pediatric population suggest that it is a safe adjunct to posterior spine fusions of the occipitocervical, cervical, thoracic, lumbar, and lumbosacral spine. There were no new cases of cancer, or degeneration or metastasis of existing malignancies in this series.",
keywords = "Bone morphogenetic protein, Cancer, Complications, Malignancy, Neurosurgery, Oncology, Pediatric spine, RhBMP-2, Spinal fusion, Spinal instrumentation, Technique",
author = "Christina Sayama and Matthew Willsey and Murali Chintagumpala and Alison Brayton and Valentina Brice{\~n}o and Ryan, {Sheila L.} and Luerssen, {Thomas G.} and Hwang, {Steven W.} and Andrew Jea",
year = "2015",
month = "7",
day = "1",
doi = "10.3171/2014.10.PEDS14199",
language = "English (US)",
volume = "16",
pages = "4--13",
journal = "Journal of neurosurgery. Pediatrics",
issn = "1933-0707",
publisher = "American Association of Neurological Surgeons",
number = "1",

}

TY - JOUR

T1 - Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer

AU - Sayama, Christina

AU - Willsey, Matthew

AU - Chintagumpala, Murali

AU - Brayton, Alison

AU - Briceño, Valentina

AU - Ryan, Sheila L.

AU - Luerssen, Thomas G.

AU - Hwang, Steven W.

AU - Jea, Andrew

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Object: The aim of this study was to determine the safety of recombinant human bone morphogenetic protein-2 (rhBMP-2) use in posterior instrumented fusions in the pediatric population, focusing on cancer risk. In a previous study, the authors reported the short-term (mean follow-up of 11 months) safety and efficacy of rhBMP-2 in the pediatric age group. The present study reports their results with a minimum of 24 months' follow-up. methods: The authors retrospectively reviewed 57 consecutive cases involving pediatric patients who underwent posterior occiptocervical, cervical, thoracic, lumbar, or lumbosacral spine fusion from October 1, 2007, to June 30, 2011, at Texas Children's Hospital. Seven cases were excluded from further analysis because of loss to follow-up. Three patients died during the follow-up period and were placed in a separate cohort. results The patients' average age at the time of surgery was 11 years, 4 months (range 9 months to 20 years). The mean duration of follow-up was 48.4 months (range 24-70 months). Cancer status was determined at the most recent encounter with the patient and/or caretaker(s) in person, or in telephone follow-up. Twenty-four or more months after administration of rhBMP-2, there were no cases of new malignancy, degeneration, or metastasis of existing tumors. The cause of death of the patients who died during the study period was not related to BMP or to the development, degeneration, or metastasis of cancer. conclusions Despite the large number of adult studies reporting increased cancer risk associated with BMP use, the authors' outcomes with rhBMP-2 in the pediatric population suggest that it is a safe adjunct to posterior spine fusions of the occipitocervical, cervical, thoracic, lumbar, and lumbosacral spine. There were no new cases of cancer, or degeneration or metastasis of existing malignancies in this series.

AB - Object: The aim of this study was to determine the safety of recombinant human bone morphogenetic protein-2 (rhBMP-2) use in posterior instrumented fusions in the pediatric population, focusing on cancer risk. In a previous study, the authors reported the short-term (mean follow-up of 11 months) safety and efficacy of rhBMP-2 in the pediatric age group. The present study reports their results with a minimum of 24 months' follow-up. methods: The authors retrospectively reviewed 57 consecutive cases involving pediatric patients who underwent posterior occiptocervical, cervical, thoracic, lumbar, or lumbosacral spine fusion from October 1, 2007, to June 30, 2011, at Texas Children's Hospital. Seven cases were excluded from further analysis because of loss to follow-up. Three patients died during the follow-up period and were placed in a separate cohort. results The patients' average age at the time of surgery was 11 years, 4 months (range 9 months to 20 years). The mean duration of follow-up was 48.4 months (range 24-70 months). Cancer status was determined at the most recent encounter with the patient and/or caretaker(s) in person, or in telephone follow-up. Twenty-four or more months after administration of rhBMP-2, there were no cases of new malignancy, degeneration, or metastasis of existing tumors. The cause of death of the patients who died during the study period was not related to BMP or to the development, degeneration, or metastasis of cancer. conclusions Despite the large number of adult studies reporting increased cancer risk associated with BMP use, the authors' outcomes with rhBMP-2 in the pediatric population suggest that it is a safe adjunct to posterior spine fusions of the occipitocervical, cervical, thoracic, lumbar, and lumbosacral spine. There were no new cases of cancer, or degeneration or metastasis of existing malignancies in this series.

KW - Bone morphogenetic protein

KW - Cancer

KW - Complications

KW - Malignancy

KW - Neurosurgery

KW - Oncology

KW - Pediatric spine

KW - RhBMP-2

KW - Spinal fusion

KW - Spinal instrumentation

KW - Technique

UR - http://www.scopus.com/inward/record.url?scp=84964694124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964694124&partnerID=8YFLogxK

U2 - 10.3171/2014.10.PEDS14199

DO - 10.3171/2014.10.PEDS14199

M3 - Article

C2 - 25860984

AN - SCOPUS:84964694124

VL - 16

SP - 4

EP - 13

JO - Journal of neurosurgery. Pediatrics

JF - Journal of neurosurgery. Pediatrics

SN - 1933-0707

IS - 1

ER -